A method for treating acute myeloid leukemia (AML), such as poor risk AML, byadministering to a subject in need thereof an effective amount of Mubritinibor apharmaceutically acceptable salt thereof is disclosed. The AML to be treatedmay becharacterized by certain features, such as high level of expression of one ormore Homeobox(HOX)-network genes, high and/or low expression of specific genes, thepresence of one ormore cytogenetic or molecular risk factors such as Normal Karyotype (NK),mutated NPM1,mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1,mutatedIDH2, mutated RUNX1, mutated WT1, mutated SRSF2, mutated CSF3R, intermediatecytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/orabnormalchromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.
